- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.03. | CDC panel mulls changes to RSV vaccine recommendation | ||
| 01.03. | Gritstone to lay off 40% of workforce after costly study delay | ||
| 29.02. | Cure Ventures backs a cell therapy startup targeting Parkinson's | ||
| 29.02. | With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease | ||
| 29.02. | Abingworth invests in Trodelvy development in deal with Gilead | ||
| 28.02. | Incannex says psilocybin therapy lowered anxiety in small study | ||
| 28.02. | Women's health company Obseva to wind down, lay off staff | ||
| 28.02. | Viatris pays $350M to gain two drugs from Idorsia | ||
| 28.02. | Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup | ||
| 27.02. | Viking Therapeutics data suggest obesity drug could rival Zepbound, Wegovy | ||
| 27.02. | Janux shares triple on early cancer immunotherapy data | ||
| 27.02. | Denali, fresh off study setback, gets $500M lift | ||
| 27.02. | Minerva schizophrenia drug rejected by FDA | ||
| 26.02. | Humira biosimilar from Alvotech, Teva wins FDA approval on third attempt | ||
| 26.02. | GSK drug meets goal in late-stage gonorrhea study | ||
| 26.02. | NGM to go private through deal with investment firm | ||
| 26.02. | Obesity drug from Boehringer, Zealand succeeds in MASH trial | ||
| 26.02. | Choosing laboratory equipment with workplace experience in mind | ||
| 23.02. | J&J secures EMA backing for earlier CAR-T use in multiple myeloma | ||
| 23.02. | BioMarin preaches patience amid slow sales for hemophilia gene therapy | ||
| 22.02. | Frontier gets $80M, Galapagos' backing to make a better KRAS drug | ||
| 22.02. | Biden administration pledges $100M toward women's health research | ||
| 22.02. | Moderna pitches RSV shot, new vaccines after 'difficult year of transition' | ||
| 22.02. | ORI Capital, the venture firm behind CG's big IPO, raises new biotech fund | ||
| 22.02. | Novavax agrees to pay Gavi in settlement over COVID vaccine contract |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
